Allakos (ALLK.US) is down more than 77% today after releasing disappointing results from clinical trials of its drug AK006. The drug was intended to treat Chronic Spontaneous Urticaria (CSU), but the phase 1 trial results did not demonstrate sufficient therapeutic activity. As a result, the company has decided to abandon the project, which was one of its leading programs. Following the discontinuation of the project, the company announced it will lay off 75% of its workforce and will begin a review of available strategies to find a new alternative for its future operations.
Source: xStation
Daily summary: Silver plunges 9% ๐จIndices, crypto and precious metals under pressure
Does the current sell-off signal the end of quantum companies?
Howmet Aerospace surges 10% after earnings reaching $100 bilion market cap ๐
US Open: Cisco Systems slides 10% after earnings ๐ Mixed sentiments on Wall Street